Who is rsv dangerous for

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Respiratory syncytial virus (RSV) is most dangerous for infants under 6 months old, older adults over 65, and individuals with chronic medical conditions. In the United States, RSV causes approximately 58,000-80,000 hospitalizations and 100-300 deaths annually in children under 5, and about 60,000-160,000 hospitalizations with 6,000-10,000 deaths in adults 65+.

Key Facts

RSV causes 58,000-80,000 hospitalizations annually in U.S. children under 5
RSV leads to 100-300 deaths per year in U.S. children under 5
Adults 65+ experience 60,000-160,000 RSV hospitalizations annually in the U.S.
6,000-10,000 deaths occur yearly in U.S. adults 65+ from RSV
Premature infants have 2-3 times higher RSV hospitalization risk than full-term infants

Overview

Respiratory syncytial virus (RSV) is a common respiratory virus that typically causes mild, cold-like symptoms in healthy adults and older children. First identified in 1956, RSV has since been recognized as a leading cause of lower respiratory tract infections worldwide, particularly affecting vulnerable populations during seasonal outbreaks that typically occur from late fall to early spring. The virus spreads through respiratory droplets when an infected person coughs or sneezes, and can survive on surfaces for several hours, making it highly contagious in community settings.

While most people recover from RSV within 1-2 weeks, the virus poses significant dangers to specific high-risk groups who may develop severe complications requiring hospitalization. According to the Centers for Disease Control and Prevention (CDC), RSV infections result in substantial healthcare burdens annually, with infants, older adults, and immunocompromised individuals facing the greatest risks. Understanding which populations are most vulnerable helps guide prevention strategies, clinical management, and public health interventions to reduce RSV-related morbidity and mortality.

How It Works

RSV infection progresses differently across age groups and health statuses, with severity determined by both viral factors and host vulnerabilities.

Infants and Young Children: RSV is the most common cause of bronchiolitis and pneumonia in children under 1 year old in the United States. Approximately 1-2% of infants under 6 months with RSV infection require hospitalization, with premature infants facing 2-3 times higher risk than full-term infants. The small airways of infants become easily obstructed by inflammation and mucus production, leading to respiratory distress that may require oxygen support or mechanical ventilation.
Older Adults: Adults aged 65+ experience age-related declines in immune function (immunosenescence) that increase RSV severity. Approximately 3-7% of older adults with RSV infection require hospitalization, with those having underlying conditions facing the highest risks. RSV can exacerbate chronic conditions like COPD and heart failure, leading to prolonged recovery times and increased mortality.
Immunocompromised Individuals: People with weakened immune systems from conditions like cancer, HIV/AIDS, or immunosuppressive medications have reduced ability to clear RSV infections. Transplant recipients face particularly high risks, with RSV mortality rates reaching 30-80% in hematopoietic stem cell transplant patients who develop lower respiratory tract infections.
Chronic Medical Conditions: Individuals with chronic heart or lung diseases, neuromuscular disorders, or metabolic conditions experience worse RSV outcomes. Adults with congestive heart failure have 2.5 times higher risk of RSV hospitalization, while those with COPD face 3-4 times higher risk compared to healthy adults.

Key Comparisons

Feature	Infants & Young Children	Older Adults (65+)
Annual Hospitalizations (U.S.)	58,000-80,000	60,000-160,000
Annual Deaths (U.S.)	100-300	6,000-10,000
Primary Complications	Bronchiolitis, pneumonia	Exacerbation of chronic conditions
Highest Risk Subgroups	Premature infants, congenital heart disease	COPD, congestive heart failure
Prevention Options	Maternal vaccination, monoclonal antibodies	RSV vaccines

Why It Matters

Healthcare Burden: RSV creates substantial economic costs, with annual U.S. healthcare expenditures estimated at $1.5-2.5 billion for pediatric cases alone. Hospital stays average 3-5 days for infants and 5-7 days for older adults, straining healthcare systems during seasonal peaks when pediatric ICU beds may reach 90% capacity.
Long-term Consequences: Severe RSV infection in infancy increases later asthma risk by 30-50%, creating lifelong respiratory vulnerability. Older adults who survive RSV hospitalization face increased frailty, with 25-40% experiencing functional decline that reduces independence and quality of life.
Prevention Advances: Recent developments in RSV prevention offer significant protection, with maternal RSV vaccination reducing infant hospitalization risk by 57% and monoclonal antibody treatment (nirsevimab) lowering hospitalization risk by 75% in infants. Adult RSV vaccines approved in 2023 provide 82-94% protection against severe disease in older adults.

Understanding RSV's disproportionate impact on vulnerable populations enables targeted prevention and treatment strategies that can save lives and reduce healthcare burdens. As new vaccines and monoclonal antibodies become more widely available, healthcare providers can implement evidence-based approaches to protect those at highest risk. Continued research into RSV pathogenesis, improved diagnostics, and equitable access to preventive measures will be crucial for reducing global RSV morbidity and mortality in coming years, particularly as climate change may alter traditional seasonal patterns of transmission.